Terug
64
Ook genoteerd als
NONOF
OTC
Dagbereik
€ 36,55
€ 37,20
52-Weeksbereik
€ 35,85
€ 81,44
Volume
15.255.543
50D / 200D Gem.
€ 48,31
/
€ 54,90
Vorige Slotkoers
€ 36,82
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1,7 | 0,3 |
| P/B | 0,8 | 2,9 |
| ROE % | 58,4 | 3,7 |
| Net Margin % | 33,1 | 3,8 |
| Rev Growth 5Y % | 20,5 | 10,0 |
| D/E | 0,7 | 0,2 |
Koersdoel Analisten
Hold
€ 47,00
+27.4%
Low: € 42,00
High: € 54,00
Forward K/W
1,8
Forward WPA
€ 20,82
WPA Groei (sch.)
+0,0%
Omzet Sch.
290 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 28,01
€ 25,65 – € 31,35
|
360 B | 5 |
| FY2029 |
€ 25,76
€ 23,59 – € 28,84
|
340 B | 2 |
| FY2028 |
€ 23,26
€ 21,30 – € 26,03
|
320 B | 5 |
Belangrijkste Punten
Revenue grew 20,53% annually over 5 years — strong growth
ROE of 58,36% indicates high profitability
Net margin of 33,14% shows strong profitability
Generating 28,99B in free cash flow
P/E of 1,66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 18,19%
Groei
Revenue Growth (5Y)
20,53%
Revenue (1Y)2,34%
Earnings (1Y)-2,46%
FCF Growth (3Y)-35,65%
Kwaliteit
Return on Equity
58,36%
ROIC29,96%
Net Margin33,14%
Op. Margin43,69%
Veiligheid
Debt / Equity
0,67
Current Ratio0,80
Interest Coverage19,92
Waardering
P/E Ratio
1,66
P/B Ratio0,84
EV/EBITDA2,07
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2,34% | Revenue Growth (3Y) | 13,12% |
| Earnings Growth (1Y) | -2,46% | Earnings Growth (3Y) | 8,49% |
| Revenue Growth (5Y) | 20,53% | Earnings Growth (5Y) | 19,84% |
| Profitability | |||
| Revenue (TTM) | 297,20B | Net Income (TTM) | 98,50B |
| ROE | 58,36% | ROA | 18,14% |
| Gross Margin | 80,34% | Operating Margin | 43,69% |
| Net Margin | 33,14% | Free Cash Flow (TTM) | 28,99B |
| ROIC | 29,96% | FCF Growth (3Y) | -35,65% |
| Safety | |||
| Debt / Equity | 0,67 | Current Ratio | 0,80 |
| Interest Coverage | 19,92 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 1,66 | P/B Ratio | 0,84 |
| P/S Ratio | 0,55 | PEG Ratio | 8,49 |
| EV/EBITDA | 2,07 | Dividend Yield | 0,03% |
| Market Cap | 163,94B | Enterprise Value | 268,43B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 297,20B | 290,40B | 232,26B | 176,95B | 140,80B |
| Net Income | 98,50B | 100,99B | 83,68B | 55,53B | 47,76B |
| EPS (Diluted) | 23,03 | 22,63 | 18,62 | 12,22 | 10,37 |
| Gross Profit | 238,77B | 245,88B | 196,50B | 148,51B | 117,14B |
| Operating Income | 129,83B | 128,34B | 102,57B | 74,81B | 58,64B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 542,90B | 465,80B | 314,49B | 241,26B | 194,51B |
| Total Liabilities | 348,86B | 322,31B | 207,93B | 157,77B | 123,76B |
| Shareholders' Equity | 194,05B | 143,49B | 106,56B | 83,49B | 70,75B |
| Total Debt | 130,96B | 102,79B | 27,01B | 25,78B | 26,65B |
| Cash & Equivalents | 26,46B | 15,66B | 14,39B | 12,65B | 10,72B |
| Current Assets | 172,45B | 160,90B | 139,65B | 108,19B | 85,60B |
| Current Liabilities | 215,66B | 217,53B | 169,66B | 120,94B | 99,52B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#73 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026